Added to YB: 2026-09-14
Pitch date: 2026-09-10
ZURA [neutral]
Zura Bio Limited
Author Info
No bio for this author
Company Info
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
Market Cap
$547.2M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.69
P/E
-5.25
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference coverage, Day 2 Section 1 - Zura Bio Limited
ZURA (quick overview): Zura Bio’s bispecific antibody combines validated IL-17 blockade with BAFF inhibition, testing whether dual targeting can improve hidradenitis suppurativa outcomes. The 247-patient Phase 2 SHIELD study is powered for HiSCR75, with management viewing a roughly 20-point placebo-adjusted improvement as meaningful. The key uncertainty is whether BAFF adds enough efficacy to justify greater complexity; exclusion of prior IL-17 users limits insight into treatment-resistant patients.
Read full article (2 min)